Chargement en cours...

Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma

Targeting MAPK pathway in mutant BRAF melanoma with the specific BRAF inhibitor vemurafenib showed robust initial responses in the majority of patients followed by relapses due to acquired resistance to the drug. In (V600E)BRAF melanoma cell lines, senescence-associated β-galactosidase activity is o...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Krayem, Mohammad, Najem, Ahmad, Journe, Fabrice, Morandini, Renato, Sales, François, Awada, Ahmad, Ghanem, Ghanem E.
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2018
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6112757/
https://ncbi.nlm.nih.gov/pubmed/30159130
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25879
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!